Krystal Biotech (KRYS) Other Non-Current Liabilities (2018 - 2026)
Krystal Biotech (KRYS) posted quarterly Other Non-Current Liabilities of $7.1 million for Q2 2026, up 152.86% year-over-year from $2.8 million in Q2 2025, and up 38.17% on a QoQ basis from $5.1 million in Q1 2026.
Krystal Biotech (KRYS) Other Non-Current Liabilities (2018 - 2026) Analysis & Trends
Krystal Biotech has reported Other Non-Current Liabilities for 4 years, with the latest figure at $7.1 million in Q2 2026.
- Other Non-Current Liabilities for Q2 2026 came in at $7.1 million, up 152.86% year-over-year; the trailing twelve-month figure through Jun 2026 was $7.1 million (up 152.86% YoY), and the FY2025 annual result was $3.7 million, up 162.44% from the prior year.
- Other Non-Current Liabilities climbed to $7.1 million in Q2 2026, from $5.1 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $7.1 million in Q2 2026 and troughed at $588000.0 in Q2 2024.
- A 3-year average of $3.0 million and a median of $2.8 million in 2025 frame the typical range for Other Non-Current Liabilities.
- The widest annual swing landed in 2025, when Other Non-Current Liabilities soared 376.19%; it then surged 152.86% in 2026.
- A 3-year view of Other Non-Current Liabilities shows it stood at $1.4 million in 2024, then soared by 162.44% to $3.7 million in 2025, then surged by 90.12% to $7.1 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $7.1 million in Q2 2026, $5.1 million in Q1 2026, and $3.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.08 Mn |
| Mar 31, 2026 | 5.10 Mn |
| Dec 31, 2025 | 3.72 Mn |
| Sep 30, 2025 | 3.10 Mn |
| Jun 30, 2025 | 2.79 Mn |
| Mar 31, 2025 | 2.00 Mn |
| Dec 31, 2024 | 1.42 Mn |
| Sep 30, 2024 | 761,000.00 |
| Jun 30, 2024 | 588,000.00 |
| Dec 31, 2018 | 294,000.00 |
| Sep 30, 2018 | 245,000.00 |